|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
gptkb:GAVI_Alliance
gptkb:COVAX_Facility
gptkb:various_countries
gptkb:African_Union
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:United_States
Phase 3
|
|
gptkbp:collaborations
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:National_Institutes_of_Health
gptkb:University_of_Queensland
|
|
gptkbp:community_health
|
gptkb:significant
|
|
gptkbp:developed_by
|
gptkb:GSK
gptkb:Sanofi
|
|
gptkbp:dosage_form
|
recommended
two doses
|
|
gptkbp:effective_date
|
gptkb:2021
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GSK-Sanofi COVID-19 vaccine
|
|
gptkbp:is_effective_against
|
approximately 90%
|
|
gptkbp:is_vulnerable_to
|
gptkb:complex
global
international
multiple regions
substantial
essential
recombinant DNA technology
accelerated due to pandemic
adjuvanted vaccine
Vidprevtyn
|
|
gptkbp:manufacturing_partner
|
gptkb:Bharat_Biotech
|
|
gptkbp:market_authorization
|
gptkb:European_Medicines_Agency
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:route_of_administration
|
intramuscular injection
|
|
gptkbp:safety_measures
|
ongoing
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
injection site reactions
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
protein subunit vaccine
|
|
gptkbp:vaccine_approval_status
|
authorized for emergency use
|
|
gptkbp:vaccine_clinical_trial_results
|
positive
|
|
gptkbp:vaccine_distribution_partners
|
various NGOs
|
|
gptkbp:vaccine_efficacy_study
|
published in medical journals
|
|
gptkbp:vaccine_impact_on_herd_immunity
|
potentially significant
|
|
gptkbp:vaccine_monitoring_adverse_events
|
required
|
|
gptkbp:vaccine_production_capacity
|
increased due to demand
|
|
gptkbp:vaccine_public_awareness_campaign
|
ongoing
|
|
gptkbp:vaccine_public_health_strategy
|
integrated into national plans
|
|
gptkbp:whoemergency_use_listing
|
yes
|
|
gptkbp:bfsParent
|
gptkb:GSK
|
|
gptkbp:bfsLayer
|
4
|